Zhdanava M et al. Esketamine Nasal Spray for Major Depressive Disorder With Acute Suicidal Ideation or Behavior: Description of Treatment Access, Utilization, and Claims-Based Outcomes in the ...

Ketamine or more specifically, its cousin — esketamine — has started to change the landscape of depression, especially where it borders on suicide. Ketamine may help severely depressed, study ...

A nasal spray version of esketamine was more effective for depression that is resistant to treatment than a more commonly used drug, research published Wednesday in The New England Journal of ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

Esketamine Nasal Spray . view more . ... Moreover, in order to guide clinicians and patients in their decision-making, and to be adopted by health insurance companies and governments, ...

Esketamine plus SNRI cohort showed better survival probability than esketamine pls SSRI group. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

Spravato nasal spray, also known as esketamine, can now be used to treat depression in adults with treatment-resistant depression. $3,500 iPhone possible? What to know 📋 How to talk money 🤑 ...

After screening and randomization, 95 patients received 84 mg esketamine, 86 patients received 56 mg esketamine, and 197 received placebo. About 61% were female, 86.8% were white, and 65.6% were ...

BARCELONA — Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca), an atypical antipsychotic, for treatment-resistant depression (TRD ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.